Jim Simons Humanigen, Inc Transaction History

Renaissance Technologies LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$0.13 - $0.2 $10,335 - $15,900	-79,500 Reduced 81.37%	18,200 $3,000
Q1 2023 May 12, 2023	SELL	$0.12 - $0.23 $167,288 - $320,636	-1,394,071 Reduced 93.45%	97,700 $14,000
Q4 2022 Feb 13, 2023	BUY	$0.09 - $0.2 $56,346 - $125,214	626,071 Added 72.32%	1,491,771 $179,000
Q3 2022 Nov 14, 2022	BUY	$0.15 - $3.02 $129,855 - $2.61 Million	865,700 New	865,700 $156,000

558K

Ticker HGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,661,000
Description
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.